ID LSHR_RAT STANDARD; PRT; 700 AA.
AC P16235; P70646; Q63807; Q63808; Q63809;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 01-OCT-2000 (Rel. 40, Last annotation update)
DE LUTROPIN-CHORIOGONADOTROPIC HORMONE RECEPTOR PRECURSOR (LH/CG-R)
DE (LSH-R) (LUTEINIZING HORMONE RECEPTOR).
GN LHCGR.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=89332512; PubMed=2502842;
RA McFarland K.C., Sprengel R., Phillips H.S., Koehler M.,
RA Rosemblit N., Nikolics K., Segaloff D.L., Seeburg P.H.;
RT "Lutropin-choriogonadotropin receptor: an unusual member of the G
RT protein-coupled receptor family.";
RL Science 245:494-499(1989).
RN [2]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RC STRAIN=SPRAGUE-DAWLEY; TISSUE=Ovary;
RX MEDLINE=92347604; PubMed=1353463;
RA Aatsinki J.T., Pietila E.M., Lakkakorpi J.T., Rajaniemi H.J.;
RT "Expression of the LH/CG receptor gene in rat ovarian tissue is
RT regulated by an extensive alternative splicing of the primary
RT transcript.";
RL Mol. Cell. Endocrinol. 84:127-135(1992).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=91209270; PubMed=2019252;
RA Koo Y.B., Slaughter R.G., Ji T.H.;
RT "Structure of the luteinizing hormone receptor gene and multiple
RT exons of the coding sequence.";
RL Endocrinology 128:2297-2308(1991).
RN [4]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RX MEDLINE=91006819; PubMed=1976554;
RA Bernard M.P., Myers R.V., Moyle W.R.;
RT "Cloning of rat lutropin (LH) receptor analogs lacking the soybean
RT lectin domain.";
RL Mol. Cell. Endocrinol. 71:R19-R23(1990).
RN [5]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RX MEDLINE=91126285; PubMed=2281186;
RA Segaloff D.L., Sprengel R., Nikolics K., Ascoli M.;
RT "Structure of the lutropin/choriogonadotropin receptor.";
RL Recent Prog. Horm. Res. 46:261-303(1990).
RN [6]
RP SEQUENCE OF 295-700 FROM N.A.
RX MEDLINE=91060531; PubMed=2174034;
RA Tsai-Morris C.H., Buczko E., Wang W., Dufau M.L.;
RT "Intronic nature of the rat luteinizing hormone receptor gene defines
RT a soluble receptor subspecies with hormone binding activity.";
RL J. Biol. Chem. 265:19385-19388(1990).
RN [7]
RP SEQUENCE OF 27-37.
RX MEDLINE=89174723; PubMed=2925659;
RA Roche P.C., Ryan R.J.;
RT "Purification, characterization, and amino-terminal sequence of rat
RT ovarian receptor for luteinizing hormone/human choriogonadotropin.";
RL J. Biol. Chem. 264:4636-4641(1989).
RN [8]
RP MUTAGENESIS.
RX MEDLINE=91332007; PubMed=1714448;
RA Ji I., Ji T.H.;
RT "Asp383 in the second transmembrane domain of the lutropin receptor
RT is important for high affinity hormone binding and cAMP production.";
RL J. Biol. Chem. 266:14953-14957(1991).
CC -!- FUNCTION: RECEPTOR FOR LUTROPIN-CHORIOGONADOTROPIC HORMONE.
CC THE ACTIVITY OF THIS RECEPTOR IS MEDIATED BY G PROTEINS WHICH
CC ACTIVATE ADENYLATE CYCLASE.
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.
CC -!- ALTERNATIVE PRODUCTS: AT LEAST 11 ISOFORMS WHICH DIFFER IN
CC SUBCELLULAR LOCATION ARE PRODUCED BY ALTERNATIVE SPLICING
CC OF THE SAME GENE.
CC -!- SIMILARITY: BELONGS TO FAMILY 1 OF G-PROTEIN COUPLED RECEPTORS.
CC FSH/LSH/TSH SUBFAMILY.
CC -!- SIMILARITY: CONTAINS 7 LEUCINE-RICH REPEATS (LRR).
CC --------------------------------------------------------------------------
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC --------------------------------------------------------------------------
DR EMBL; M26199; AAA41528.1; -.
DR EMBL; M61212; AAA41527.1; -.
DR EMBL; M61211; AAA41527.1; JOINED.
DR EMBL; S40803; AAB22680.1; -.
DR EMBL; S40787; AAB22680.1; JOINED.
DR EMBL; S40903; AAB22680.1; JOINED.
DR EMBL; S40904; AAB22680.1; JOINED.
DR EMBL; S40905; AAB22680.1; JOINED.
DR EMBL; S40907; AAB22680.1; JOINED.
DR EMBL; S40909; AAB22680.1; JOINED.
DR EMBL; S40918; AAB22680.1; JOINED.
DR EMBL; S40920; AAB22680.1; JOINED.
DR EMBL; S40795; AAB22680.1; JOINED.
DR EMBL; S40798; AAB22680.1; JOINED.
DR EMBL; S40795; AAB22681.1; -.
DR EMBL; S40787; AAB22681.1; JOINED.
DR EMBL; S40903; AAB22681.1; JOINED.
DR EMBL; S40904; AAB22681.1; JOINED.
DR EMBL; S40905; AAB22681.1; JOINED.
DR EMBL; S40907; AAB22681.1; JOINED.
DR EMBL; S40909; AAB22681.1; JOINED.
DR EMBL; S40918; AAB22681.1; JOINED.
DR EMBL; S40920; AAB22681.1; JOINED.
DR EMBL; S40803; AAB22682.2; -.
DR EMBL; S40787; AAB22682.2; JOINED.
DR EMBL; S40903; AAB22682.2; JOINED.
DR EMBL; S40907; AAB22682.2; JOINED.
DR EMBL; S40909; AAB22682.2; JOINED.
DR EMBL; S40918; AAB22682.2; JOINED.
DR EMBL; S40920; AAB22682.2; JOINED.
DR EMBL; S40795; AAB22682.2; JOINED.
DR EMBL; S40798; AAB22682.2; JOINED.
DR EMBL; S40803; AAB22683.1; -.
DR EMBL; S40787; AAB22683.1; JOINED.
DR EMBL; S40903; AAB22683.1; JOINED.
DR EMBL; S40904; AAB22683.1; JOINED.
DR EMBL; S40905; AAB22683.1; JOINED.
DR EMBL; S40907; AAB22683.1; JOINED.
DR EMBL; S40909; AAB22683.1; JOINED.
DR EMBL; S40918; AAB22683.1; JOINED.
DR EMBL; S40920; AAB22683.1; JOINED.
DR EMBL; S40795; AAB22683.1; JOINED.
DR EMBL; S40798; AAB22683.1; JOINED.
DR EMBL; S40803; AAB22684.2; -.
DR EMBL; S40787; AAB22684.2; JOINED.
DR EMBL; S40903; AAB22684.2; JOINED.
DR EMBL; S40904; AAB22684.2; JOINED.
DR EMBL; S40905; AAB22684.2; JOINED.
DR EMBL; S40909; AAB22684.2; JOINED.
DR EMBL; S40918; AAB22684.2; JOINED.
DR EMBL; S40920; AAB22684.2; JOINED.
DR EMBL; S40795; AAB22684.2; JOINED.
DR EMBL; S40798; AAB22684.2; JOINED.
DR EMBL; M68928; AAA41529.1; -.
DR EMBL; M68917; AAA41529.1; JOINED.
DR EMBL; M68918; AAA41529.1; JOINED.
DR EMBL; M68919; AAA41529.1; JOINED.
DR EMBL; M68920; AAA41529.1; JOINED.
DR EMBL; M68921; AAA41529.1; JOINED.
DR EMBL; M68922; AAA41529.1; JOINED.
DR EMBL; M68923; AAA41529.1; JOINED.
DR EMBL; M68925; AAA41529.1; JOINED.
DR EMBL; M68926; AAA41529.1; JOINED.
DR EMBL; M68927; AAA41529.1; JOINED.
DR PIR; A32460; A32460.
DR PIR; A41343; A41343.
DR HSSP; P22888; 1LUT.
DR GCRDb; GCR_0138; -.
DR GCRDb; GCR_0139; -.
DR GCRDb; GCR_0262; -.
DR GCRDb; GCR_0612; -.
DR GCRDb; GCR_0613; -.
DR GCRDb; GCR_0614; -.
DR InterPro; IPR000276; -.
DR InterPro; IPR001611; -.
DR InterPro; IPR002131; -.
DR InterPro; IPR002273; -.
DR Pfam; PF00001; 7tm_1; 1.
DR Pfam; PF00560; LRR; 2.
DR PRINTS; PR00373; GLYCHORMONER.
DR PRINTS; PR01144; LSHRECEPTOR.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
KW G-protein coupled receptor; Transmembrane; Glycoprotein; Signal;
KW Phosphorylation; Repeat; Leucine-rich repeat; Alternative splicing.
FT SIGNAL 1 26
FT CHAIN 27 700 LUTROPIN-CHORIOGONADOTROPIC HORMONE
FT RECEPTOR.
FT DOMAIN 27 362 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 363 390 1 (POTENTIAL).
FT DOMAIN 391 399 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 400 422 2 (POTENTIAL).
FT DOMAIN 423 443 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 444 466 3 (POTENTIAL).
FT DOMAIN 467 486 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 487 509 4 (POTENTIAL).
FT DOMAIN 510 529 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 530 551 5 (POTENTIAL).
FT DOMAIN 552 574 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 575 598 6 (POTENTIAL).
FT DOMAIN 599 609 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 610 631 7 (POTENTIAL).
FT DOMAIN 632 700 CYTOPLASMIC (POTENTIAL).
FT REPEAT 52 75 LRR 1.
FT REPEAT 126 150 LRR 2.
FT REPEAT 152 175 LRR 3.
FT REPEAT 176 200 LRR 4.
FT REPEAT 202 224 LRR 5.
FT REPEAT 225 248 LRR 6.
FT REPEAT 250 271 LRR 7.
FT DISULFID 443 518 BY SIMILARITY.
FT CARBOHYD 103 103 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 178 178 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 199 199 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 295 295 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 303 303 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 317 317 N-LINKED (GLCNAC...) (POTENTIAL).
FT VARSPLIC 83 132 MISSING (IN ISOFORM 1950).
FT VARSPLIC 133 157 MISSING (IN ISOFORM 1759).
FT VARSPLIC 184 700 MISSING (IN ISOFORM C2).
FT VARSPLIC 232 251 DISSTKLQALPSHGLESIQT -> PCRATGWSPFRRSSPC
FT LPTH (IN ISOFORM 2075).
FT VARSPLIC 232 293 MISSING (IN ISOFORM E/A2, ISOFORM EB AND
FT ISOFORM B1).
FT VARSPLIC 252 700 MISSING (IN ISOFORM 2075).
FT VARSPLIC 294 367 QNFSFSIFENFSKQCESTVRKADNETLYSAIFEENELSGW
FT DYDYGFCSPKTLQCAPEPDAFNPCEDIMGYAFLR ->
FT IFHFPFLKTSPNNAKAQLEKQITRRFIPPSLRRMNSVAGI
FT MIMASVHPRHSNVLQNQMLSTPVKILWAMPSLGS (IN
FT ISOFORM B1 AND ISOFORM B3).
FT VARSPLIC 294 294 Q -> P (IN ISOFORM C1).
FT VARSPLIC 295 700 MISSING (IN ISOFORM C1).
FT VARSPLIC 321 342 YSAIFEENELSGWDYDYGFCSP -> LHGALPAAHCLRGLP
FT NKRPVL (IN ISOFORM 1834, ISOFORM 1759 AND
FT ISOFORM EB).
FT VARSPLIC 343 700 MISSING (IN ISOFORMS 1834, ISOFORM 1759
FT AND ISOFORM EB).
FT VARSPLIC 368 700 MISSING (IN ISOFORM B1 AND ISOFORM B3).
FT VARIANT 82 82 I -> M (IN ISOFORM 1950).
FT VARIANT 179 179 E -> G (IN ISOFORM 1759).
FT VARIANT 233 233 I -> T (IN ISOFORM 1950).
FT VARIANT 646 646 G -> S (IN ISOFORM 1950).
FT MUTAGEN 409 409 D->N: SIGNIFICANT REDUCTION OF BINDING.
FT MUTAGEN 436 436 D->N: NO CHANGE IN BINDING OR CAMP PROD.
FT MUTAGEN 455 455 E->Q: NO CHANGE IN BINDING OR CAMP PROD.
FT MUTAGEN 582 582 D->N: NO CHANGE IN BINDING OR CAMP PROD.
FT CONFLICT 33 33 R -> L (IN REF. 7).
SQ SEQUENCE 700 AA; 78035 MW; 31807E73BAC94F1F CRC64;
MGRRVPALRQ LLVLAVLLLK PSQLQSRELS GSRCPEPCDC APDGALRCPG PRAGLARLSL
TYLPVKVIPS QAFRGLNEVV KIEISQSDSL ERIEANAFDN LLNLSELLIQ NTKNLLYIEP
GAFTNLPRLK YLSICNTGIR TLPDVTKISS SEFNFILEIC DNLHITTIPG NAFQGMNNES
VTLKLYGNGF EEVQSHAFNG TTLISLELKE NIYLEKMHSG AFQGATGPSI LDISSTKLQA
LPSHGLESIQ TLIALSSYSL KTLPSKEKFT SLLVATLTYP SHCCAFRNLP KKEQNFSFSI
FENFSKQCES TVRKADNETL YSAIFEENEL SGWDYDYGFC SPKTLQCAPE PDAFNPCEDI
MGYAFLRVLI WLINILAIFG NLTVLFVLLT SRYKLTVPRF LMCNLSFADF CMGLYLLLIA
SVDSQTKGQY YNHAIDWQTG SGCGAAGFFT VFASELSVYT LTVITLERWH TITYAVQLDQ
KLRLRHAIPI MLGGWLFSTL IATMPLVGIS NYMKVSICLP MDVESTLSQV YILSILILNV
VAFVVICACY IRIYFAVQNP ELTAPNKDTK IAKKMAILIF TDFTCMAPIS FFAISAAFKV
PLITVTNSKI LLVLFYPVNS CANPFLYAIF TKAFQRDFLL LLSRFGCCKR RAELYRRKEF
SAYTSNCKNG FPGASKPSQA TLKLSTVHCQ QPIPPRALTH
//